Novavax defers profitability target by a year on weak COVID vaccine sales

Novavax on Thursday deferred its target to become profitable by a year to 2028 as changes in U.S. vaccination policy have ...

Novavax, Inc. (NVAX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Jefferies London Healthcare Conference 2025 November 19, 2025 11:30 AM ESTCompany ParticipantsRuxandra Draghia-Akli - Executive VP ...
Hosted on MSN

Novavax's COVID-Flu Combo Shot Shows Strong Immune Response

Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.
The Columbian

FDA approves Novavax COVID-19 shot but with unusual restrictions

WASHINGTON (AP) — The Food and Drug Administration has issued a long-awaited approval of Novavax’s COVID-19 vaccine but with unusual restrictions. Novavax makes the nation’s only traditional ...
The Business Journals

Novavax secures FDA approval for Covid vaccine, but with unexpected limitations

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min After weeks of uncertainty and ...
Yahoo

Novavax’s COVID vaccine gets FDA approval, but with limits

A medical worker prepares ampoules of the Nuvaxovid vaccine against Covid-19 by Novavax at the Tegel vaccination center on February 28, 2022 in Berlin, Germany. This story was originally published on ...
WTVD

Novavax says COVID-19 vaccine shows 90.4% overall efficacy in US Phase 3 trial

NEW YORK -- The American biotechnology company Novavax announced on Monday that its coronavirus vaccine candidate was found to have an overall efficacy of 90.4% in a Phase 3 trial conducted across the ...